• Twitter
• Facebook
• Snapchat
• Pinterest
• LinkedIn
• Tumblr

---

Fundamental analysis: Cara Therapeutics, Inc. (CARA)

Awarener score: 3.4

Conclusion

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

• Business has been growing at an extremely fast pace. It's been more than average in relation to peer companies.
• Cara Therapeutics, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks mediocre against rivals.

Margins score: 2.5

• CARA profit margins -on goods and services sold- are usually hardly sufficient. They stand somewhat worse than rival companies.
• Business profit on sales tends to be extremely poor. It's encouraging in relation to competitors.
• Profits on sales made -available to repay debt and purchase properties- are usually extremely poor. They remain a slight improvement compared to peers.
• Earnings -before income taxes and interests on loans taken- tend to be extremely poor in relation to total revenues. They're still somewhat better than similar companies.
• Profits -before income taxes- are usually extremely poor considering total sales, and remain encouraging in relation to rivals.
• Total net profit tends to be extremely poor when confronted to sales. Company stands encouraging in relation to comparable firms.

Growth score: 2.3

• Cara Therapeutics, Inc. profit -on goods and services sold- has been growing at an extremely fast pace. It's been excellent in relation to competitors.
• In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
• In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
• In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
• In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
• In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
• The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 3.0

• CARA had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
• Research and development expenses consume a substantial portion of revenues. It's encouraging in relation to competitors.
• The company grows sparsely in relation to research and development efforts. It stands in good shape compared to rival companies.

Profitability score: 2.2

• Cara Therapeutics, Inc. usually gets very poor returns on the resources it controls. It proves encouraging in relation to peer firms.
• The company normally gets very poor proceeds -on the resources directly invested in the business-. They remain a slight improvement compared to similar companies.
• There's usually little profitability -in relation to owned resources-. It ranks encouraging in relation to competitors.
• In the past, got very poor returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's more than average in relation to comparable enterprises.

Usage of Funds score: 2.4

• CARA on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands more than average in relation to rival firms.
• The company is usually replacing some proportion of the property, plant, and equipment that gets old, saving part of the funds for something else, which is below average when measured against industry peers.
• In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
• The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
• As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
• The company usually significantly enlarges the pool of investors, resulting in more mouths feeding on the pie of profits. It remains excellent in relation to peer enterprises.
• Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
• We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 7.4

• Cara Therapeutics, Inc. has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
• The company has a lot more short-term resources than short-term obligations. There're no liquidity concerns. It turns to be rather normal in relation to similar firms.
• Almost no resources controlled were provided for with financial debt. Financial strength is great. Company could significantly increase debt if it wished so, to reinvest in business, to buy a smaller company or to reward stockholders. It remains somewhat better than rival firms.
• Most resources controlled are already cash or short-term investments, which is best for liquidity. It looks similar to rivals.
• For every dollar of short-term obligations, the company has a lot of dollars in cash and short-term receivables. It's rather normal in relation to peer firms.
• For every dollar of short-term obligations, the company has a lot of dollars in cash and equivalents, which is slightly better than similar enterprises.
• Usually, sales are on a month and a half credit. It still ranks similar to peers.
• Normally has approximately four months of sales worth in inventory. It comes up as a slight improvement compared to competitors.
• On average, it takes higher than five months from the purchase to charging customers. It happens to be slightly better than peers.
• On average pays suppliers many months after the purchase. It ranks encouraging in relation to industry peers.
• The company charges its customers long before it must pay its suppliers, so the more it sales, the more free funds it gets. It's a slight improvement compared to similar companies.
• Company earns net interest income on its investments and therefore is in a quite comfortable financial position. It stands top-notch against rival firms.
• Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
• Revenues are excellent in relation to property, plant, and equipment required to operate. This metric is likely dependent on the industry the company operates in. Low property, plant, and equipment requirements, allows the company to keep more money to reward stockholders in the long run. It looks impressive in relation to similar firms.
• Resource exploitation is low when yearly sales are considered, business volume must be significantly increased. This metric is normally tied to the industry where the firm belongs. It's still better than most peer companies.

Valuation score: 3.5

• Cara Therapeutics, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
• Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains a slight improvement compared to peers.
• In the past twelve months, the company consumed lots of funds. Either it reinvested heavily in the business or genuine fund generation might be struggling, which stands worse than most similar companies.
• The company usually consumes plenty more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving outstanding business growth, genuine profitability may be brought into question. It's still substantially worse when measured against industry firms.
• In the past twelve months, the company has enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among somewhat more stockholders. It came up a slight improvement compared to peer ventures.
• This company is sitting in a mountain of cash. It's very well poised to substantially increase stockholder payments, or to fund new business projects. It looks top-notch against similar enterprises.
• Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
• Comparing the current stock price with the past twelve-months revenues gives a very high relationship. This is an important metric to check its evolution through time, and to compare to industry peers. It looks in good shape compared to rival firms.
• The relation between the stock price and accounting book value might be reasonable. It's important both to check this metric through time and to compare it with rival companies. The company remains somewhat better than peer firms.
• In the past twelve months, the operating business lost plenty of money. It happens to be substantially worse when measured against industry peers.
• In an alternate metric of bang for the buck, the company has usually shown an extremely low earnings power ability when measured against the current stock price and financial position. Profitability is significantly in dispute. It's still in a very weak position compared to peer companies.

Total score: 3.6

---

Awarener score: 3.4

Conclusion

Support us!

We are an independent project. No ads, no suscription, no registration required.

• Donate!